GLP-1 is produced in the cells lining the intestines, which makes gut health important
But when GLP-1 drugs faced severe shortages beginning in 2022, the FDA allowed compounding pharmacies to begin producing it
However, Novo said it will continue to manage shipments of the drugs 0.25 mg starter dose to responsibly initiate patients on treatment. Novo is the maker of the wildly popular Ozempic and its weight loss counterpart Wegovy, both formulations of semaglutide
LGG stimulates the production of secretory IgA, an antibody that plays a frontline defense role in the gut and respiratory tract
This is largely because retatrutide has not yet completed the full regulatory approval process, and comprehensive drug interaction studies particularly those involving commonly used supplements have not been publicly reported
GLP-1 receptor agonists are prescription medications regardless of dose